D3-002A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours
Neo adj
HER2 Neg
ER+
tx naive
high risk
stage II/III
SYD985.003
A phase II study to compare the safety and efficacy of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-expressing recurrent advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy
Metastatic or recurrent nasopharyngeal carcinoma
No more than 1 line
Metastatic or recurrent nasopharyngeal carcinoma
First line
Advanced curatively unresectable solid tumors failing standard therapy.
HCC: must have failed at least 1 line of standard therapy
Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)
Other solid tumours: must have failed at least 1 line of standard therapy
Subscribe to our mailing list to get the updates to your email inbox...